• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Multimodal Imaging Tracks Radiation Maculopathy After Eye Plaque Therapy

by
October 29, 2026
in Cancer, Health
Reading Time: 3 mins read
0
Multimodal Imaging Tracks Radiation Maculopathy After Eye Plaque Therapy

Multimodal Imaging Tracks Radiation Maculopathy After Eye Plaque Therapy

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new narrative review synthesizes the terminology, classification, plaque-related dosimetry, imaging biomarkers, and preventive and therapeutic evidence surrounding this condition, arguing that its biology is not a single linear sequence but an overlapping web of endothelial, inflammatory, permeability, ischemic, and neuronal changes.

The review, published in Frontiers in Oncology, was based on a PubMed/MEDLINE search covering January 2000 through 24 September 2026, using combinations of terms including uveal melanoma, radiation retinopathy, plaque brachytherapy, the radioisotopes iodine-125, ruthenium-106, palladium-103 and cesium-131, and imaging and treatment keywords such as OCT, OCT angiography, fluorescein angiography, laser speckle flowgraphy, anti-VEGF agents, corticosteroids and laser. Seminal pre-2000 studies that defined classification, natural history or treatment were retained, and original clinical studies were prioritized for efficacy and imaging claims while reviews supplied context.

A central message concerns structural optical coherence tomography. The authors note that OCT can reveal macular edema before ophthalmoscopic radiation retinopathy becomes visible, making it a sensitive early-detection tool. However, they caution that retinal thickness changes are not specific to edema: they can also reflect neuronal swelling in earlier phases and late atrophy, so thickness alone cannot be interpreted as a single disease stage.

OCT angiography adds a perfusion dimension by detecting capillary-density loss and changes in the foveal avascular zone. Yet the review stresses that these measurements depend on signal quality and segmentation accuracy and are especially vulnerable to distortion in the presence of cystoid macular edema. Fluorescein angiography therefore remains important for assessing leakage and wide-field ischemic burden, while laser speckle flowgraphy is characterized as an investigational perfusion measure rather than an established clinical standard.

On treatment, anti-VEGF therapy emerges as the best-supported option for established radiation-related macular edema, but with an important caveat: it generally requires sustained dosing rather than short-course intervention. Prophylactic anti-VEGF cohorts show lower rates of edema and some other radiation complications, yet long-term visual superiority is not consistently demonstrated, and randomized, plaque-specific evidence is still lacking.

Corticosteroids and laser treatment retain selective roles in the management algorithm, according to the review, rather than serving as universal alternatives to anti-VEGF therapy.

The authors conclude that surveillance should be multimodal and individualized according to tumor location, patient-specific dosimetry, visual potential, and serial structural and perfusion findings. In their framing, OCT angiography complements rather than replaces structural OCT and angiography, and no validated OCTA threshold currently justifies initiating treatment in an otherwise unaffected eye.

Prospective studies, they argue, must now define reproducible biomarkers and treatment triggers so that early detection can be translated into evidence-based intervention. Until then, the review positions careful, individualized multimodal monitoring as the practical foundation for preserving vision in patients treated with plaque brachytherapy for uveal melanoma.

Subject of Research: Multimodal imaging biomarkers and management of radiation maculopathy after plaque brachytherapy for uveal melanoma

Article Title: Early detection and management of radiation maculopathy after plaque brachytherapy for uveal melanoma: a multimodal imaging narrative review

Article References: Gonzalez-Cortes, J. H., Gonzalez-Cantu, J. E., Folgar, A. M., Pelayes, D., & Mohamed-Hamsho, J. (2026). Early detection and management of radiation maculopathy after plaque brachytherapy for uveal melanoma: a multimodal imaging narrative review. Frontiers in Oncology, 16, Article 1926816. https://doi.org/10.3389/fonc.2026.1926816

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1926816

Keywords: radiation maculopathy, uveal melanoma, plaque brachytherapy, radiation retinopathy, optical coherence tomography, OCT angiography, fluorescein angiography, anti-VEGF, laser speckle flowgraphy, retinal ischemia, macular edema, Early

News Source: Nathaniel Bowman. (October 29, 2026). Multimodal Imaging Tracks Radiation Maculopathy After Eye Plaque Therapy. Scienmag.

Tags: anti-VEGFearlyfluorescein angiographylaser speckle flowgraphymacular edemaOCT angiographyoptical coherence tomographyplaque brachytherapyradiation maculopathyradiation retinopathyretinal ischemiauveal melanoma
Share12Tweet7Share2ShareShareShare1

Related Posts

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

October 30, 2026
Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

October 30, 2026

Serum and urine protein biomarkers may sharpen prostate cancer detection beyond PSA

October 30, 2026

One gene locus flags atrial fibrillation risk after major surgery, UK Biobank study finds

October 30, 2026

POPULAR NEWS

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    29 shares
    Share 12 Tweet 7
  • Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

    29 shares
    Share 12 Tweet 7
  • ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

    29 shares
    Share 12 Tweet 7
  • Systematic review maps sustainability tensions in offshore wind development

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.